A light-driven therapy of pancreatic adenocarcinoma using gold nanorods-based nanocarriers for co-delivery of doxorubicin and siRNA

Feng Yin, Chengbin Yang, Qianqian Wang, Shuwen Zeng, Rui Hu, Guimiao Lin, Jinglin Tian, Siyi Hu, Rong Feng Lan, Ho Sup Yoon, Fei Lu, Kuan Wang, Ken Tye Yong

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

In this work, we report the engineering of polyelectrolyte polymers coated Gold nanorods (AuNRs)-based nanocarriers that are capable of co-delivering small interfering RNA (siRNA) and an anticancer drug doxorubicin (DOX) to Panc-1 cancer cells for combination of both chemo- and siRNA-mediated mutant K-Ras gene silencing therapy. Superior anticancer efficacy was observed through synergistic combination of promoted siRNA and DOX release upon irradiating the nanoplex formulation with 665 nm light. Our antitumor study shows that the synergistic effect of AuNRs nanoplex formulation with 665 nm light treatment is able to inhibit the in vivo tumor volume growth rate by 90%. The antitumor effect is contributed from the inactivation of K-Ras gene and thereby causing a profound synthesis (S) phase arrest in treated Panc-1 cells. Our study shows that the percentage of Panc-1 cells treated by nanoplex formulation with S phase is determined to be 35% and it is 17% much higher than that of Panc-1 cells without any treatments. The developed nanotherapy formulation here, that combines chemotherapy, RNA silencing and NIR window light-mediated therapy, will be seen to be the next natural step to be taken in the clinical research for improving the therapeutic outcomes of the pancreatic adenocarcinoma treatment.

Original languageEnglish
Pages (from-to)818-833
Number of pages16
JournalTheranostics
Volume5
Issue number8
DOIs
Publication statusPublished - Jan 1 2015
Externally publishedYes

Fingerprint

Animal Disease Models
Nanotubes
Induced Hyperthermia
Drug Carriers
Phototherapy
Tumor Cell Line
Pancreatic Neoplasms
Nude Mice
Gold
Antineoplastic Agents
Doxorubicin
Small Interfering RNA
Cell Survival
Adenocarcinoma
Light
ras Genes
S Phase
Neoplasms
Therapeutic Human Experimentation
Gene Silencing

Keywords

  • AuNRs
  • Doxorubicin
  • K-Ras
  • Pancreatic adenocarcinoma
  • SiRNA
  • Tumors

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

A light-driven therapy of pancreatic adenocarcinoma using gold nanorods-based nanocarriers for co-delivery of doxorubicin and siRNA. / Yin, Feng; Yang, Chengbin; Wang, Qianqian; Zeng, Shuwen; Hu, Rui; Lin, Guimiao; Tian, Jinglin; Hu, Siyi; Lan, Rong Feng; Yoon, Ho Sup; Lu, Fei; Wang, Kuan; Yong, Ken Tye.

In: Theranostics, Vol. 5, No. 8, 01.01.2015, p. 818-833.

Research output: Contribution to journalArticle

Yin, F, Yang, C, Wang, Q, Zeng, S, Hu, R, Lin, G, Tian, J, Hu, S, Lan, RF, Yoon, HS, Lu, F, Wang, K & Yong, KT 2015, 'A light-driven therapy of pancreatic adenocarcinoma using gold nanorods-based nanocarriers for co-delivery of doxorubicin and siRNA', Theranostics, vol. 5, no. 8, pp. 818-833. https://doi.org/10.7150/thno.11335
Yin, Feng ; Yang, Chengbin ; Wang, Qianqian ; Zeng, Shuwen ; Hu, Rui ; Lin, Guimiao ; Tian, Jinglin ; Hu, Siyi ; Lan, Rong Feng ; Yoon, Ho Sup ; Lu, Fei ; Wang, Kuan ; Yong, Ken Tye. / A light-driven therapy of pancreatic adenocarcinoma using gold nanorods-based nanocarriers for co-delivery of doxorubicin and siRNA. In: Theranostics. 2015 ; Vol. 5, No. 8. pp. 818-833.
@article{fa5c1f8c1bab4fdda511d59269919d86,
title = "A light-driven therapy of pancreatic adenocarcinoma using gold nanorods-based nanocarriers for co-delivery of doxorubicin and siRNA",
abstract = "In this work, we report the engineering of polyelectrolyte polymers coated Gold nanorods (AuNRs)-based nanocarriers that are capable of co-delivering small interfering RNA (siRNA) and an anticancer drug doxorubicin (DOX) to Panc-1 cancer cells for combination of both chemo- and siRNA-mediated mutant K-Ras gene silencing therapy. Superior anticancer efficacy was observed through synergistic combination of promoted siRNA and DOX release upon irradiating the nanoplex formulation with 665 nm light. Our antitumor study shows that the synergistic effect of AuNRs nanoplex formulation with 665 nm light treatment is able to inhibit the in vivo tumor volume growth rate by 90{\%}. The antitumor effect is contributed from the inactivation of K-Ras gene and thereby causing a profound synthesis (S) phase arrest in treated Panc-1 cells. Our study shows that the percentage of Panc-1 cells treated by nanoplex formulation with S phase is determined to be 35{\%} and it is 17{\%} much higher than that of Panc-1 cells without any treatments. The developed nanotherapy formulation here, that combines chemotherapy, RNA silencing and NIR window light-mediated therapy, will be seen to be the next natural step to be taken in the clinical research for improving the therapeutic outcomes of the pancreatic adenocarcinoma treatment.",
keywords = "AuNRs, Doxorubicin, K-Ras, Pancreatic adenocarcinoma, SiRNA, Tumors",
author = "Feng Yin and Chengbin Yang and Qianqian Wang and Shuwen Zeng and Rui Hu and Guimiao Lin and Jinglin Tian and Siyi Hu and Lan, {Rong Feng} and Yoon, {Ho Sup} and Fei Lu and Kuan Wang and Yong, {Ken Tye}",
year = "2015",
month = "1",
day = "1",
doi = "10.7150/thno.11335",
language = "English",
volume = "5",
pages = "818--833",
journal = "Theranostics",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",
number = "8",

}

TY - JOUR

T1 - A light-driven therapy of pancreatic adenocarcinoma using gold nanorods-based nanocarriers for co-delivery of doxorubicin and siRNA

AU - Yin, Feng

AU - Yang, Chengbin

AU - Wang, Qianqian

AU - Zeng, Shuwen

AU - Hu, Rui

AU - Lin, Guimiao

AU - Tian, Jinglin

AU - Hu, Siyi

AU - Lan, Rong Feng

AU - Yoon, Ho Sup

AU - Lu, Fei

AU - Wang, Kuan

AU - Yong, Ken Tye

PY - 2015/1/1

Y1 - 2015/1/1

N2 - In this work, we report the engineering of polyelectrolyte polymers coated Gold nanorods (AuNRs)-based nanocarriers that are capable of co-delivering small interfering RNA (siRNA) and an anticancer drug doxorubicin (DOX) to Panc-1 cancer cells for combination of both chemo- and siRNA-mediated mutant K-Ras gene silencing therapy. Superior anticancer efficacy was observed through synergistic combination of promoted siRNA and DOX release upon irradiating the nanoplex formulation with 665 nm light. Our antitumor study shows that the synergistic effect of AuNRs nanoplex formulation with 665 nm light treatment is able to inhibit the in vivo tumor volume growth rate by 90%. The antitumor effect is contributed from the inactivation of K-Ras gene and thereby causing a profound synthesis (S) phase arrest in treated Panc-1 cells. Our study shows that the percentage of Panc-1 cells treated by nanoplex formulation with S phase is determined to be 35% and it is 17% much higher than that of Panc-1 cells without any treatments. The developed nanotherapy formulation here, that combines chemotherapy, RNA silencing and NIR window light-mediated therapy, will be seen to be the next natural step to be taken in the clinical research for improving the therapeutic outcomes of the pancreatic adenocarcinoma treatment.

AB - In this work, we report the engineering of polyelectrolyte polymers coated Gold nanorods (AuNRs)-based nanocarriers that are capable of co-delivering small interfering RNA (siRNA) and an anticancer drug doxorubicin (DOX) to Panc-1 cancer cells for combination of both chemo- and siRNA-mediated mutant K-Ras gene silencing therapy. Superior anticancer efficacy was observed through synergistic combination of promoted siRNA and DOX release upon irradiating the nanoplex formulation with 665 nm light. Our antitumor study shows that the synergistic effect of AuNRs nanoplex formulation with 665 nm light treatment is able to inhibit the in vivo tumor volume growth rate by 90%. The antitumor effect is contributed from the inactivation of K-Ras gene and thereby causing a profound synthesis (S) phase arrest in treated Panc-1 cells. Our study shows that the percentage of Panc-1 cells treated by nanoplex formulation with S phase is determined to be 35% and it is 17% much higher than that of Panc-1 cells without any treatments. The developed nanotherapy formulation here, that combines chemotherapy, RNA silencing and NIR window light-mediated therapy, will be seen to be the next natural step to be taken in the clinical research for improving the therapeutic outcomes of the pancreatic adenocarcinoma treatment.

KW - AuNRs

KW - Doxorubicin

KW - K-Ras

KW - Pancreatic adenocarcinoma

KW - SiRNA

KW - Tumors

UR - http://www.scopus.com/inward/record.url?scp=84934764963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934764963&partnerID=8YFLogxK

U2 - 10.7150/thno.11335

DO - 10.7150/thno.11335

M3 - Article

VL - 5

SP - 818

EP - 833

JO - Theranostics

JF - Theranostics

SN - 1838-7640

IS - 8

ER -